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b0Objectives: To assess the value of DWI with its two components (DWI-b1000 and DWI b0)
images in assessment of active MS and in defining dissemination in time (DIT) and dissem-
ination in space (DIS) in those patients.
Methods: Brain MRI studies were performed using T1WI, T2WI, FLAIR and DWI and CE
T1WI.
Results: Twenty-one patients (Males/Females = 6/15) of age range 18–50 years were
included. Forty lesions were hyperintense on DWI-b1000 that had significant link to
enhancement seen on contrast-enhanced T1WI (100%) indicating disease activity. Using
the 2010 revised McDonald criteria: In 9 patients (42.85%), there were [Asymptomatic
active lesions (n = 17)]. Those lesions were simultaneously present along with [Non-
active demyelinating lesions]; DIT could be diagnosed in these cases based alone on MRI
findings. In 12 patients (57.14%), there was simultaneous presence of [Symptomatic active
lesions (n = 23)]. Those lesions were present along with [Non-active demyelinating
lesions]; DIT could be diagnosed in these cases based on both clinical and MRI findings.
Conclusion: DWI-b1000 is of the same sensitivity as CE T1WI in detection of MS active
lesions and in detection of DIT and DIS. DWI-b0 can substitute the T2WI in detection of
demyelinating lesions and in confirmation of the MS disease beyond the active stage.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by
Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/4.0/).1. Introduction
Although the decision to diagnose multiple sclerosis
(MS) is commonly based originally on history, clinical data,
CNS imaging by MRI through detecting multiple lesions on
MRI Imaging over different times can reinforce, add value,or even substitute some given criteria from clinical exam-
ination [1,2].
Confirmation of lesions disseminated in time (DIT) and
disseminated in space (DIS) is required for the diagnosis of
MS [3–5]. Based on the revised McDonald MRI criteria,
diagnosis of MS can be confirmed by the detection of
‘‘any two, any new” lesions. DIS is diagnosed when there
is P1 T2-weighted imaging (T2WI) lesion in each of P2
of 4 diagnostic sites: periventricular, juxtacortical, poste-
rior fossa and spinal cord. DIT is diagnosed when any
new T2WI lesion, regardless of timing, is detected by MRI
or if contrast enhanced lesions are concurrently visualized
along with non-contrast enhanced lesions [6].
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the 2010 revisions of McDonald criteria permit for the first
time the establishment of MS diagnosis based on one sin-
gle MRI study that can show DIS and DIT (a concurrent
visualization of non-contrast enhanced lesions along with
non-symptomatic contrast enhanced lesions) [6]. The diag-
nosis of DIT can be established by the presence of new
T2WI or gadolinium enhanced lesion on a follow-up MRI,
using baseline MRI examination as a reference, irrespective
of when the baseline MRI was done [7].
With the use of Gadolinium, the active lesions will
show enhancement pattern on contrast enhanced T1WI
(CE T1WI). This is attributed to the disturbance of the
blood brain barrier. The pattern of enhancement can be
homogeneous, ring, or heterogeneous. Almost all T2WI
lesions will have gadolinium enhancement when they first
develop, however the period during which these lesions
remain active with enhanced pattern, is usually short. It
ranges from few days to few weeks [8–11]. The distinction
between active and chronic lesions is somewhat arbitrary
because several factors can affect enhancement such as
the following: the dose of gadolinium (Gd), the delay and
characteristics of image acquisition, and steroid treatment
of acute attacks [12–14].
Diffusion-weighted imaging (DWI) is a non-invasive
MRI sequence that supplies image contrast dependent on
the molecular movement of water. It is achieved by
applying a pair of magnetic field gradient pulses in a
T2-Weighted MR imaging (T2WI) sequence. The sensitivity
to water diffusion is defined by the gradient factor b or
(b value) sec/mm2 which is a factor that reflects the
strength and timing of the gradients used to generate
diffusion-weighted images. The higher the b-value, the
stronger the diffusion effects [15].
DWI sequence is actually T2 weighted sequence, sensi-
tized to diffusion by gradients. The quantitative evaluation
of diffusivity can be gained by obtaining two sets of images
with dissimilar b-values. In clinical rehearsal, one of the
b-values would measure 1000 sec/mm2 while the other
b-value is 0 sec/mm2, (yielding the so-called b0 images).
At a b value of 0 sec/mm2, T2-weighted contrast predomi-
nates while at high b-values, diffusion and T2-weighted
contrast competes but the contrast is largely produced by
the diffusion properties [16].
Recent advance in MR systems has made it possible to
acquire whole brain diffusion-weighted imaging (DWI) in
less than one minute. Therefore, many institutions have
added DWI to a routine protocols for MRI brain scanning
[16]. The use of DWI in the MRI protocol for imaging MS
appears to be of clinical value and does not have significant
increase in the whole scanning time [17].
As a practical matter, most routine clinical DWI
for examining the central nervous system currently use
b-values (b1000 and b0). The diffusion weighted sequence
through applying the two b values (b1000 and b0) will pro-
vide two images: one is DWI-b1000 image that represents
the diffusion properties and can be used in the detection of
the acute/ active demyelinating MS plaques which appear
as bright signal. The other image obtained from DWI isDWI-b0 image. This DWI-b0 image is obtained without
any additional time and has the T2WI sequence properties.
In theory it is expected that the presence of DWI sequence
including both the DWI-b1000 and DWI-b0 Images can
provide full evaluation of MS cases; DWI-b1000 can be
used for detection of MS active lesions. In the same time
DWI-b0 can substitute the T2WI in detection of demyeli-
nating lesions and in confirmation of the MS disease
beyond the active stage without the need for extra scan-
ning time [18].
2. Aim of the work
The aims of this study were to assess the value of DWI
with its two components (DWI-b1000 and DWI b0) images
in assessment of active MS and in defining dissemination
in time (DIT) and dissemination in space (DIS) in those
patients.
3. Patients and methods
3.1. Patients
The Inclusion Criteria for selection of patients in this
current study were as follows: (1) Patients who were
diagnosed as definite MS according to the McDonald’s
clinical diagnostic Criteria for diagnosing multiple sclero-
sis by experienced consultant neurologist [6]. (2) The
start of the MS disease was in the age from 15 to
50 years; (3) Baseline MRI scans were done within
14 days from start of symptoms. Exclusion criteria were
patients who received drugs such as interferon or steroids
before start of MRI scanning to exclude the possibility of
their impact upon the edema or contrast enhancement of
lesions.
Twenty-one patients met these criteria during the per-
iod of this prospective study that was conducted in Assiut
University Hospital between March 2012 and November
2015. This study was approved by the Review Board of
the institution and informed consent was attained from
all patients prior to scanning.
3.2. Methods of examinations
All patients were subjected to the following:
(1) Full history taking and clinical examination: history
was taken from the patients. Neurological clinical
examination was conducted.
(2) Radiological and imaging investigations: Brain MRI
was acquired using 1.5-Tesla Philips Superconduct-
ing Magnet System (Gyroscan ACS-NT) power track
6000 at Assiut University Hospital according to the
following protocol; Axials; T1WI, T2WI, and FLAIR
sequences, Sagittal T2WI or FLAIR, and Axials, coro-
nals, and sagittals CE T1WI after injection of
0.1 mmol/kg of Gd DTPA. DWI was done using a
single-shot echo planar spin-echo sequence with
two b values (1000 and 0 sec/mm2).
Table 1
Distribution of demyelinating lesions.
Type of lesions No of
patients
[Symptomatic active demyelinating lesions
(n = 23)] + [Non-active demyelinating lesions]
12 (57.14%)
[Asymptomatic active demyelinating lesions
(n = 17)] + [Non-active demyelinating lesions]
9 (42.85%)
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For all patients, date and time of MRI from the onset of
clinical symptoms were recorded. The appearance of dif-
ferent signal intensities of the detected lesions was
recorded in DWI (DWI-b1000 and DWI-b0 images), T2WI,
FLAIR and Post Gd T1WI. The appearance of lesions on CE
T1WI (enhanced or non-enhanced) was used as the criteria
for the diagnosis of disease activity. Signal intensity
(hyper-intense or non-hyper-intense) of any lesion on
DWI-b1000 was compared to the appearance of enhanced
lesions on CE T1WI. Lesions detected in DWI-b0 image
were compared with the lesions detected in T2WI.
According to the findings in this study, the lesions were
classified into two groups: Group 1:- (Active demyelinat-
ing lesions); these were sub-classified into two categories
according to the signal intensities of the lesions on DWI-
b1000, CE T1WI and T2WI/DWI-b0 images. Category 1
lesions: ‘‘Symptomatic active lesions”; lesions that had
hyper-intense (bright) signal on DWI-b1000 and show
enhancement on CE T1WI, simultaneously these lesions
had bright signals in both T2WI and DWI-b0 images. Cate-
gory 2 lesions: ‘‘Asymptomatic active lesions”; lesions that
had hyper-intense signal on DWI-b1000 and enhancing
on CE T1WI, but were not seen in both T2WI and DWI-b0
images. Group 2; (Non-active demyelinating lesions);
lesions that had non-hyper-intense signal on DWI-b1000
and non-enhancing on CE T1WI, in same time these lesions
had bright signals in T2WI and DWI-b0 images.
3.4. Statistical methods
Descriptive statistical analysis was done with IBM SPSS
Statistics software release 21; SPSS Inc. for windows
(Microsoft).
4. Results
Twenty-one patients (Males/Females = 6/15) with clini-
cally definite MS, with their age range (18–50 years)
(mean; 32.2 years, ±8.9) complied with the selection crite-
ria. The 21 patients had converted to clinical definite MS
with intervals ranged from 2 to 20 months after the initial
clinical existence of the disease (mean: 6.7 months ± 5.3).
The time gap between start of symptoms and baseline
brain MRI scanning ranged from 1 to 14 days (mean:
6.1 days ± 3.6).
In the current study, all the 21 brain MRI examinations
showed multiple active and non-active lesions in the char-
acteristic sites for MS.
Forty lesions were hyper-intense (bright) on DWI-
b1000 that had significant link to the seen enhancement
on contrast enhanced T1WI (100%) indicating disease
activity. Thirty-four of these enhancing lesions showed
homogenous contrast enhancement, while the remaining
6 lesions showed ring enhancement.
In 9 patients (42.85%), there were [Asymptomatic active
lesions (Category 2 lesions) (n = 17)]. Those lesions were
simultaneously present along with [Non-active demyeli-
nating lesions]. The presence of these lesions signifies thediagnosis of active MS disease with DIT based on the
revised McDonald criteria. In four out of those 9 patients,
the distribution of the (active and non-active) demyelinat-
ing lesions was at areas’ characteristic to the diagnosis of
MS signifying that lesions in these 4 cases also met the
MRI criteria of DIS. Based on revised McDonald criteria,
both the DIT and DIS could be diagnosed in these cases
based alone on MRI Findings (Table 1) and (Figs. 1 and 2).
In 12 patients (57.14%), there was simultaneous pres-
ence of [symptomatic active lesions (Category 1 lesions)
(n = 23)]. Those lesions in the 12 patients were present
along with [Non-active demyelinating lesions]. The pres-
ence of this pattern of lesions signifies the activity of the
disease. Based on revised McDonald criteria, DIT was diag-
nosed in these cases based on both clinical and MRI Find-
ings (Table 1) and (Fig. 3).
In the current study all MS lesions that appeared hyper-
intense (bright) signals in DWI-b0 were significantly linked
to hyper intensity of lesions in T2WI.5. Discussion
Adding MRI to diagnosis and monitoring of MS was a
great advance. It helped to appreciate the realistic record
of the disease [11] and to detect DIT and DIS even before
they are evident clinically [19].
One of the most important items to be considered in the
assessment of MS patients is the differentiation of MS dis-
ease activity from older lesions beyond the active stage;
this could be achieved by the use of CE T1WI that shows
enhancement of the active lesions which happens due to
the increase in the blood brain barrier permeability and
the use of DWI-b1000 that shows the active lesions as
hyper-intense (bright) signals; the contrast provided by
DWI-b1000 depends on the molecular movement of water
[9,18]. In the present research forty lesions were hyper-
intense (bright) on DWI-b1000 that had significant link
to the seen enhancement on contrast enhanced T1WI
(100%) indicating disease activity. These results match
with the results of Lo et al., 2014 who found that all 51
enhancing MS lesions in the CE T1WI were hyper-intense
in DWI [20].
Proper diagnosis and assessment of MS are essential for
disease management. Eliminating different lesions that
may simulate MS, besides the demonstration of DIS and
DIT of the pathological process should be fulfilled for diag-
nosis of the disease [7]. One of the important lesions that
should be excluded in diagnosis of active MS lesions is
the acute ischemic infarct lesions. This can be achieved
with the use of CE T1WI that may aid in differentiation
Fig. 1. (a–f); (a) Axial T2WI. (b) Axial DWI-b0 showed multiple bright lesions in the right and left periventricular white matter regions (arrows). (c) Axial CE
T1WI showed faint ring enhancing lesion at the left high parietal lobe (arrow). (d) Axial DWI-b1000 shows bright signal of the lesion (arrow). (e) Axial CE
T1WI shows small faint homogenous enhancing lesion at the left pons (arrow). (f) Axial DWI-b1000 shows bright signal of the left pontine lesion (arrow).
These lesions signify MS disease activity; DIT and DIS were based alone on MRI findings.
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both have bright signal in DWI; the usual presentation
for active MS lesions is to show enhancement while noenhancement could be elicited with acute ischemic
infarcts [17]. In this study exclusion of acute ischemic
infarct lesions was defined by detecting the pattern of
Fig. 2. (a–d); (a) Axial T2WI. (b) Axial DWI-b0 showed multiple bright lesions in the right and left periventricular white matter regions (arrows). (c) Axial CE
T1WI shows faint homogenous enhancing lesion at the right pons (arrow). (d) Axial DWI shows bright signal of the right pontine lesion (arrow). These
lesions signify MS disease activity; DIT and DIS were based alone on MRI findings.
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forty bright lesions in DWI-b1000 that may signify active
MS disease showed contrast enhancement in the CE
T1WI, with none of these lesions showed non-
enhancement in the CE T1WI confirming the diagnosis of
active MS lesions and excluding the possibility of being
acute ischemic infarcts. These results correspond with
the results of Lo et al., 2014 who used the same criteria
of differentiation of the acute ischemic infarcts from those
of active MS lesions and stated that all the 51 enhancing
MS lesions in the CE T1WI were hyper-intense in DWI
and none of these bright active lesions in DWI showed
non-enhancement in CE T1WI [20].
In the current study, overall lesion conspicuity of active
MS lesions on DWI-b1000 was superior to that on CE T1WI
images. The increased noticeability of lesions in DWI could
be explained by previous studies due to a high difference in
signal intensities between lesions and background, which
results from suppression of signal from freely movable
water protons. This fabulous background inhibition allows
the detection of even very small, acute lesions at approxi-mately any anatomic location within the brain parench-
yma [21,22].
Based on the 2010 revisions of McDonald criteria, iden-
tification of DIT could be achieved by a single MRI that
shows the coexistence presence of asymptomatic contrast
enhanced and non-enhancing lesions in MS patients, how-
ever defining DIT has a lower sensitivity due to fewer
asymptomatic enhancing brain lesions that can be seen
on a single baseline MRI. In the current study 9 patients
(42.85%) fulfilled this criteria by using CE T1WI, T2WI
and DWI with its two components (DWI-b1000 and DWI-
b0) image findings with 100% sensitivity for the diagnosis.
The results in this study is higher than the results of the
study by Lo et al. 2014 where the sensitivity was 45.5%
[20]. This could be explained by false positive lesions in
DWI were described in studies which used extended time
window of up to 45 days between symptom onset and
baseline brain MRI [20]. This long interval showed a lot
of false positive lesions that show hyper-intense (bright)
signals on DWI and did not show enhancement on contrast
enhanced T1WI. This could be explained by the
Fig. 3. (a–d); (a) Axial T2WI brain. (b) Axial DWI-b0 showed bright lesion in the right high parietal lobe (arrows). (c) Axial CE T1WI shows small faint ring
enhancing lesion at the right high parietal lobe (arrow). (d) Axial DWI-b1000 shows bright signal of the lesion (arrow). These lesions signify MS disease
activity; DIT and DIS were based on clinical and MRI findings.
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fusion in the lesions lasts longer than lesion enhancement
caused by transient disturbance in the Blood brain barrier
[8–10]. This problem of false positive lesions in DWI was
overcome by using short gap between the start of symp-
toms and baseline MRI: up to 14 days in this study and
up to 30 days in Rovira et al., 2009 [23].
In this study, four out of those 9 patients diagnosed as
DIT simultaneously met the MRI DIS criteria; the same
results were obtained by using the MRI findings on both
the DWI-b1000 and CE T1WI. These results differ from
results by Lo et al. 2014 who found that there was discrep-
ancy of the number of cases that were simultaneously
diagnosed as DIT and DIS based on the findings of CE
T1WI from that based on DWI. Nine out of those 12 DIT
cases were simultaneously diagnosed as DIS based on CE
T1WI findings while 11 out of 12 cases diagnosed as DIS
based on DWI findings, and this could be explained by falsepositive results in DWI came from the extended time per-
iod between the symptom onset and baseline MRI up to
45 days in their study [20]. This problem was overcome
in this study by using the short gap between the start of
symptoms and baseline MRI of up to 14 days.
In the current research, all MS lesions that appeared
hyper-intense in DWI-b0 were significantly linked to hyper
intensity of lesions in T2WI. Since DWI-b0 image comes
with DWI sequence, therefore, it imposes no additional
time and may serve as T2WI images, and it could be used
for validation of the diagnosis of MS. To our knowledge
no existing studies compare the results of using DWI-b0
image obtained from DWI with that of T2WI or using the
combination of both DWI-b1000 and DWI-b0 in assess-
ment of MS lesions. We believe that this is the first work
that studied the use of DWI sequence which takes less than
one minute with its two components (DWI b-1000 and
DWI-b0) in assessment of MS patients.
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of CE T1WI in detection of active MS lesions and DWI-b0
showed the same sensitivity as T2WI in the detection of
old MS lesions beyond the active stage. So the use of
DWI with its two components (DWI-b1000 and DWI-b0
images) can substitute the use of both CE T1WI and
T2WI in assessment of MS disease activity and in detection
of DIT and DIS in single MRI study according to the 2010
revised McDonald criteria especially in patients with irri-
tability and/or psychiatric manifestations that require
rapid examinations to avoid deterioration of patient’s con-
dition and motion artifacts or in cases where Gadolinium
MRI contrast is contraindicated as in cases with renal
insufficiency. In another cases with non-conclusive pattern
of MS lesions seen in CE T1WI and T2WI, the use of DWI
sequence with its two components (DWI-b1000 and
DWI-b0 images) can also be used to support the diagnosis
of MS lesions seen in both CE T1WI and T2WI.6. Conclusion
DWI offers both DWI-b1000 and DWI-b0 images that
can be used independently for evaluation of patients with
MS. DWI-b1000 is of the same sensitivity as CE T1WI in
detection of MS active lesions and according to the revised
McDonald criteria; using DWI-b1000 in the protocol for
examining the MS patients will help in the diagnosis of
the disease, its activity and also in detection of DIT an
DIS in a single baseline MRI. In the same time DWI-b0
can substitute the T2WI in detection of demyelinating
lesions and in confirmation of the MS disease beyond the
active stage.Authors’ contributions
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